As the obesity clinical trials evolve, there is a growing emphasis on how decentralisation and new technologies can play a ...

Pfizer has announced data from the Phase III trial of TALZENNA plus XTANDI in patients with metastatic castration-resistant ...

The trial is funded in part by a $30m grant from the US Biomedical Advanced Research and Development Authority (BARDA).

The technology is part of a broader industry shift towards precision medicine, says GlobalData analyst Cynthia Stinchcombe.

DiaMedica Therapeutics has received the SAHPRA approval to commence a Phase II trial of DM199 to treat preeclampsia.

Chicago-based Vanqua Bio’s Parkinson’s disease drug has shown proof-of-concept in a first-in-human study, with the company to ...

InnoCare Pharma has announced that its Phase II study of the TYK2 inhibitor ICP-488 for psoriasis treatment met the primary ...

Priovant expects topline data from two Phase III trials for its dual TYK2 and Jak1 inhibitor in dermatomyositis and uveitis ...

Cassava alleged that the short sellers had launched a “short and distort” campaign which caused a “decline in Cassava ...

Allurion has added more efficacy and safety data to support its intragastric balloon, but popularity of GLP-1 drugs shows no ...

Gamifying clinical trials could motivate participants to engage better with trial platforms and advance research.

The company plans to study the application of molecular residual disease (MRD) testing in breast cancer management using its ...